Cancer patients with acute coronary syndrome have non-superior bleeding risk compared to patients with similar characteristics – a propensity score analysis from the ProACS registry

Saúde, 2020 2018, Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1736, 10.1016/S0140-6736(18)32203-7 Pothineni, 2017, Temporal trends and outcomes of acute myocardial infarction in patients with cancer, Ann Transl Med, 5, 482, 10.21037/atm.2017.11.29 Navi, 2017, Risk of arterial thromboembolism in patients with cancer, J Am Coll Cardiol, 22, 926, 10.1016/j.jacc.2017.06.047 Guha, 2019, Acute coronary syndromes in cancer patients: the differences of ACS in cancer patients and the general population are discussed, Eur Heart J, 40, 1487, 10.1093/eurheartj/ehz267 Banasiak, 2018, Optimal management of cancer patients with acute coronary syndrome, Pol Arch Intern Med, 30, 244 Potts, 2019, Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States, Eur Heart J, 40, 1790, 10.1093/eurheartj/ehy769 Roule, 2020, Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention, BMC Cardiovasc Disord, 20, 38, 10.1186/s12872-020-01352-0 Koene, 2016, Shared risk factors in cardiovascular disease and cancer, Circulation, 133, 1104, 10.1161/CIRCULATIONAHA.115.020406 Yetis Sayin, 2018, Acute coronary syndrome in cancer patients, Am J Cardiovasc Drugs, 18, 361, 10.1007/s40256-018-0286-z Zamorano, 2016, 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology, Eur Heart J, 37, 2768, 10.1093/eurheartj/ehw211 Shah, 2018, Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation, Blood Adv, 13, 200, 10.1182/bloodadvances.2017010694 Eikelboom, 2006, Adverse impact of bleeding on prognosis in patients with acute coronary syndromes, Circulation, 114, 774, 10.1161/CIRCULATIONAHA.106.612812 Al-Hawwas, 2018, Acute coronary syndrome management in cancer patients, Curr Oncol Rep, 22, 78, 10.1007/s11912-018-0724-8 Park, 2019, Acute coronary syndromes in patients with active hematologic malignancies – incidence, management, and outcomes, Int J Cardiol, 15, 6, 10.1016/j.ijcard.2018.10.008 Collet, 2021, 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J, 42, 1289, 10.1093/eurheartj/ehaa575 Donisan, 2019, Cardiac interventional procedures in cardio-oncology patients, Cardiol Clin, 37, 469, 10.1016/j.ccl.2019.07.012 Iannaccone, 2017, Optimal medical therapy in patients with malignancy undergoing percutaneous coronary intervention for acute coronary syndrome: a BleeMACS sub-study, Am J Cardiovasc Drugs, 17, 61, 10.1007/s40256-016-0196-x Quintana, 2020, Outcomes following percutaneous coronary intervention in patients with cancer, Int J Cardiol, 300, 106, 10.1016/j.ijcard.2019.09.016 Wang, 2016, Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction, Mayo Clin Proc, 91, 1680, 10.1016/j.mayocp.2016.06.029 Landes, 2017, Long-term outcomes after percutaneous coronary interventions in cancer survivors, Coron Artery Dis, 28, 5, 10.1097/MCA.0000000000000429 The GUSTO Investigators, 1993, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction, N Engl J Med, 329, 673, 10.1056/NEJM199309023291001 Bharadwaj, 2020, Outcomes of percutaneous coronary interventions in cancer patients, Expert Rev Cardiovasc Ther, 18, 25, 10.1080/14779072.2020.1718493 Iannaccone, 2018, Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy, Eur Heart J Acute Cardiovasc Care, 7, 631, 10.1177/2048872617706501 Desai, 2018, Radiation-associated cardiac disease – a practical approach to diagnosis and management, JACC Cardiovasc Imag, 11, 1132, 10.1016/j.jcmg.2018.04.028 Yusuf, 2012, Treatment and outcomes of acute coronary syndrome in the cancer population, Clin Cardiol, 35, 443, 10.1002/clc.22007 Urban, 2019, Defining high bleeding risk in patients undergoing percutaneous coronary intervention, Circulation, 140, 240, 10.1161/CIRCULATIONAHA.119.040167 Delluc, 2019, Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH, J Thromb Haemost, 17, 1247, 10.1111/jth.14478 Raposeiras-Roubín, 2018, Development and external validation of a post-discharge bleeding risk score in patients with acute coronary syndrome: the BleeMACS score, Int J Cardiol, 254, 10, 10.1016/j.ijcard.2017.10.103 Mosarla, 2019, Anticoagulation strategies in patients with cancer: jacc review topic of the week, J Am Coll Cardiol, 73, 1336, 10.1016/j.jacc.2019.01.017 Chen, 2019, Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF, Eur Heart J Qual Care Clin Outcomes, 5, 145, 10.1093/ehjqcco/qcy040 Melloni, 2017, Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE Trial, Am J Med, 130, 1440, 10.1016/j.amjmed.2017.06.026 Fanola, 2018, Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF – TIMI 48 Trial, J Am Heart Assoc, 7, e008987, 10.1161/JAHA.118.008987 Undas, 2020, antagonist oral anticoagulants in cancer patients with atrial fibrillation, Anatol J Cardiol, 23, 10 Deng, 2019, Antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis, J Am Heart Assoc, 8, e012540, 10.1161/JAHA.119.012540 Iliescu, 2018, Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia, Am J Cardiol, 122, 1465, 10.1016/j.amjcard.2018.07.033 Sarkiss, 2007, Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes, Cancer, 109, 621, 10.1002/cncr.22434 Styczkiewicz, 2020, Clinical presentation and treatment of acute coronary syndrome as well as 1-year survival of patients hospitalized due to cancer: a 7-year experience of a nonacademic center, Medicine (Baltimore), 99, e18972, 10.1097/MD.0000000000018972 Velders, 2013, Elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention, Am J Cardiol, 112, 1867, 10.1016/j.amjcard.2013.08.019 Nabiałek-Trojanowska, 2019, Acute coronary syndrome in patients undergoing anticancer therapies: a single-center, controlled case study, Adv Clin Exp Med, 28, 1667, 10.17219/acem/110316 Cordero, 2018, Prevalence and postdischarge incidence of malignancies in patients with acute coronary syndrome, Rev Esp Cardiol (Engl Ed), 71, 267, 10.1016/j.recesp.2017.07.004 Iliescu, 2016, Catheter Cardiovasc Interv, 87, E202, 10.1002/ccd.26379